Teleflex (Teleflex) ROCE % : 4.96% (As of Dec. 2023)

View and export this data going back to 1994. Start your Free Trial

What is Teleflex ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Teleflex's annualized ROCE % for the quarter that ended in Dec. 2023 was 4.96%.

Teleflex ROCE % Historical Data

The historical data trend for Teleflex's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Teleflex ROCE % Chart

Teleflex Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

7.34

6.86

9.63

7.98

7.82

Teleflex Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															8.23	7.30	9.13	10.43	4.96

Teleflex ROCE % Calculation

Teleflex's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	519.094	/	( ( (6928.063 - 581.492)	+	(7532.546 - 606.745) )	/ 2 )
	=	519.094	/	( (6346.571	+	6925.801)	/ 2 )
	=	519.094	/	6636.186
	=	7.82 %

Teleflex's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	343.052	/	( ( (7493.634 - 585.422)	+	(7532.546 - 606.745) )	/ 2 )
	=	343.052	/	( ( 6908.212	+	6925.801 )	/ 2 )
	=	343.052	/	6917.0065
	=	4.96 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Teleflex (NYSE:TFX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Teleflex ROCE % Related Terms

Thank you for viewing the detailed overview of Teleflex's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Teleflex (Teleflex) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Teleflex Inc (NYSE:TFX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

T1FX34:Brazil

Address

550 East Swedesford Road, Suite 400, Wayne, PA, USA, 19087

Website

https://www.teleflex.com

Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2022 sales), interventional (16%), anesthesia (14%), surgical (14%), interventional urology (12%), original-equipment manufacturing (10%), and all other (10%). Geographic exposure for the business is primarily in the U.S., which accounts for 60% of revenue, with international markets making up the remainder.

Executives

Liam Kelly	officer: EVP & President, International	IDA BUSINESS AND TECHNOLOGY PARK, DUBLIN ROAD, ATHLONE L2 00000
Thomas E Powell	officer: Senior Vice President & CFO	C/O TOMOTHERAPY INCORPORATED, 1240 DEMING WAY, MADISON WI 53717
Stuart A Randle	director	585 WEST 500 SOUTH, BOUNTIFUL UT 84010
Jaewon Ryu	director	950 N. GLEBE ROAD, SUITE 700, ARLINGTON VA 22203
Neena M Patil	director	JAZZ PHARMACEUTICALS, 3170 PORTER DRIVE, PALO ALTO CA 94304
Andrew A Krakauer	director	CANTEL MEDICAL CORP., 150 CLOVE ROAD, 9TH FLOOR, LITTLE FALLS NJ 07424
Cameron P Hicks	officer: Vice President, Global HR	550 E. SWEDESFORD ROAD, SUITE 400, WAYNE PA 19087
Klasko Stephen K. M.d.	director	155 SOUTH LIMERICK ROAD, LIMERICK PA 19468
Jay White	officer: VP & Pres, Global Commercial	3015 CARRINGTON MILL BLVD., MORRISVILLE NC 27560
Daniel V. Logue	officer: VP, Gen Counsel & Secretary	550 E. SWEDESFORD ROAD, SUITE 400, WAYNE PA 19087
John Deren	officer: VP & Chief Accounting Officer	550 E. SWEDESFORD ROAD, SUITE 400, WAYNE PA 19087
James J Leyden	officer: VP, General Counsel, Secretary	C/O INFRASOURCE SERVICES, INC, 500 WEST DUTTON MILL ROAD, ASTON PA 19014
James Winters	officer: Vice President, Mfg and Supply	550 E. SWEDESFORD ROAD, SUITE 400, WAYNE PA 19087
Mario Wijker	officer: Vice President, QARA	550 E. SWEDESFORD ROAD, SUITE 400, WAYNE PA 19087
Benson Smith	director	C/O ROCHESTER MEDICAL INC, ONE ROCHESTER MEDICAL DDRIVE, STEWARTVILLE MN 55976